Rhythm Biosciences Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

David Atkins

Chief Executive Officer (CEO)

AU$409.2k

Compensación total

Porcentaje del salario del CEO	12.1%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	6yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Dec 03

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de David Atkins en comparación con los beneficios de Rhythm Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	AU$409k	AU$49k	-AU$7m

Compensación vs. Mercado: La compensación total ($USD275.68K) de David está en línea con el promedio de empresas de tamaño similar en el mercado Australian ($USD309.27K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de CEO con los resultados de la empresa.

CEO

David Atkins (59 yo)

less than a year

Permanencia

AU$409,243

Compensación

Dr. David Atkins, MBA, Ph. D., serves as Chief Executive Officer of Rhythm Biosciences Limited since May 13, 2024. He was Director of Cynata Therapeutics Limited from July 01, 2022 until November 2023. He...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Atkins	Chief Executive Officer	less than a year	AU$409.24k	sin datos
Guy Carisbrooke	Financial Controller	less than a year	AU$178.96k	sin datos
Andrea Steele	General Counsel & Joint Company Secretary	2.6yrs	sin datos	sin datos
James Barrie	Joint Company Secretary	less than a year	sin datos	sin datos

0.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de RHY no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Otto Buttula	Non-Executive Chairman	4.9yrs	AU$369.11k	14.64% A$ 2.2m
Louis Panaccio	Non-Executive Director	7.1yrs	AU$66.86k	0.43% A$ 65.8k
Susan MacLeman	Independent Deputy Chair	1.7yrs	AU$87.74k	sin datos
Trevor Lockett	Non-Executive Director	7.3yrs	AU$227.26k	0.68% A$ 102.4k

6.0yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de RHY se considera experimentada (5.8 años de antigüedad promedio).

Rhythm Biosciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

Executive Chairman recently bought AU$248k worth of stock

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Recent updates

Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024

New minor risk - Share price stability

New major risk - Financial position

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million.

Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million.

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

New major risk - Share price stability

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

New minor risk - Shareholder dilution

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

New minor risk - Financial data availability

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Executive Chairman recently bought AU$248k worth of stock

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited

Less than half of directors are independent

Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022

Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer

Executive Chairman recently sold AU$6.5m worth of stock

Executive Chairman exercised options to buy AU$459k worth of stock.

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers

Less than half of directors are independent

Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ®

Rhythm Biosciences Ltd Announces Executive Changes

Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding

Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7)

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Non-Executive Director David White has left the company

Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial

Rhythm Biosciences Betters ColoSTAT Results

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

New 90-day high: AU$1.64

Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site

New 90-day high: AU$1.56

Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites

New 90-day high: AU$1.38

New 90-day high: AU$0.88

Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

New 90-day high: AU$0.28

New 90-day high: AU$0.21

Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial

New 90-day high - AU$0.20

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million.

Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad